Dr. Reddy's Laboratories shares fall 1.82 percent and underperform competitors
Updated
Updated · MarketWatch · Apr 29
Dr. Reddy's Laboratories shares fall 1.82 percent and underperform competitors
16 articles · Updated · MarketWatch · Apr 29
Shares closed at 1,330.10 rupees on Wednesday, 3.47% below the 52-week high reached on June 12th.
The decline occurred during a positive session for the BSE SENSEX, which rose 0.79% to 77,496.36, while Lupin gained 0.38% and Zydus Lifesciences slipped 0.05%.
Trading volume for Dr. Reddy's reached 162,747, nearly double its 50-day average, and Wockhardt also fell 1.81% among sector peers.
Is Dr. Reddy's stock a bargain at its low valuation or a classic value trap?
Can Dr. Reddy's new weight-loss drug offset its massive expiring blockbuster revenue?
With prices slashed by 80%, who will ultimately win India's generic weight-loss drug war?
How will the new US-India tariff framework reshape the global pharmaceutical supply chain?
Will US tariff exemptions for Indian generics last, or is a trade shock looming?